Fear-potentiated	fear-potentiated	O	O
startle	startle	O	O
,	,	O	O
but	but	O	O
not	not	O	O
light-enhanced	light-enhanced	O	O
startle	startle	O	O
,	,	O	O
is	is	O	O
enhanced	enhanced	O	O
by	by	O	O
anxiogenic	anxiogenic	O	O
drugs	drugs	O	O
.	.	O	O

RATIONALE	rationale	O	O
AND	and	O	O
OBJECTIVES	objectives	O	O
:	:	O	O
The	the	O	O
light-enhanced	light-enhanced	O	O
startle	startle	O	O
paradigm	paradigm	O	O
(	(	O	O
LES	les	O	O
)	)	O	O
is	is	O	O
suggested	suggested	O	O
to	to	O	O
model	model	O	O
anxiety	anxiety	O	S_disease
,	,	O	O
because	because	O	O
of	of	O	O
the	the	O	O
non-specific	non-specific	O	O
cue	cue	O	O
and	and	O	O
the	the	O	O
long-term	long-term	O	O
effect	effect	O	O
.	.	O	O

In	in	O	O
contrast	contrast	O	O
,	,	O	O
the	the	O	O
fear-potentiated	fear-potentiated	O	O
startle	startle	O	O
(	(	O	O
FPS	fps	O	O
)	)	O	O
is	is	O	O
suggested	suggested	O	O
to	to	O	O
model	model	O	O
conditioned	conditioned	O	O
fear	fear	O	O
.	.	O	O

However	however	O	O
,	,	O	O
the	the	O	O
pharmacological	pharmacological	O	O
profiles	profiles	O	O
of	of	O	O
these	these	O	O
two	two	O	O
paradigms	paradigms	O	O
are	are	O	O
very	very	O	O
similar	similar	O	O
.	.	O	O

The	the	O	O
present	present	O	O
study	study	O	O
investigated	investigated	O	O
the	the	O	O
effects	effects	O	O
of	of	O	O
putative	putative	O	O
anxiogenic	anxiogenic	O	O
drugs	drugs	O	O
on	on	O	O
LES	les	O	O
and	and	O	O
FPS	fps	O	O
and	and	O	O
aimed	aimed	O	O
at	at	O	O
determining	determining	O	O
the	the	O	O
sensitivity	sensitivity	O	O
of	of	O	O
LES	les	O	O
for	for	O	O
anxiogenic	anxiogenic	O	O
drugs	drugs	O	O
and	and	O	O
to	to	O	O
potentially	potentially	O	O
showing	showing	O	O
a	a	O	O
pharmacological	pharmacological	O	O
differentiation	differentiation	O	O
between	between	O	O
these	these	O	O
two	two	O	O
paradigms	paradigms	O	O
.	.	O	O

METHODS	methods	O	O
:	:	O	O
Male	male	O	O
Wistar	wistar	O	O
rats	rats	O	O
received	received	O	O
each	each	O	O
dose	dose	O	O
of	of	O	O
the	the	O	O
alpha(2)-adrenoceptor	alpha(2)-adrenoceptor	O	O
antagonist	antagonist	O	O
yohimbine	yohimbine	S_chemical	O
(	(	O	O
0.25	0.25	O	O
-	-	O	O
1.0mg/kg	1.0mg/kg	O	O
)	)	O	O
,	,	O	O
the	the	O	O
5-HT(2C	5-ht(2c	O	O
)	)	O	O
receptor	receptor	O	O
agonist	agonist	O	O
m-chlorophenylpiperazine	m-chlorophenylpiperazine	O	O
(	(	O	O
mCPP	mcpp	O	O
,	,	O	O
0.5	0.5	O	O
-	-	O	O
2.0mg/kg	2.0mg/kg	O	O
)	)	O	O
or	or	O	O
the	the	O	O
GABA(A	gaba(a	O	O
)	)	O	O
inverse	inverse	O	O
receptor	receptor	O	O
agonist	agonist	O	O
pentylenetetrazole	pentylenetetrazole	O	O
(	(	O	O
PTZ	ptz	S_chemical	O
,	,	O	O
3	3	O	O
-	-	O	O
30mg/kg	30mg/kg	O	O
)	)	O	O
and	and	O	O
were	were	O	O
subsequently	subsequently	O	O
tested	tested	O	O
in	in	O	O
either	either	O	O
LES	les	O	O
or	or	O	O
FPS	fps	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
None	none	O	O
of	of	O	O
the	the	O	O
drugs	drugs	O	O
enhanced	enhanced	O	O
LES	les	O	O
,	,	O	O
whereas	whereas	O	O
mCPP	mcpp	O	O
increased	increased	O	O
percentage	percentage	O	O
FPS	fps	O	O
and	and	O	O
yohimbine	yohimbine	S_chemical	O
increased	increased	O	O
absolute	absolute	O	O
FPS	fps	O	O
values	values	O	O
.	.	O	O

Furthermore	furthermore	O	O
,	,	O	O
yohimbine	yohimbine	S_chemical	O
increased	increased	O	O
baseline	baseline	O	O
startle	startle	O	O
amplitude	amplitude	O	O
in	in	O	O
the	the	O	O
LES	les	O	O
,	,	O	O
while	while	O	O
mCPP	mcpp	O	O
suppressed	suppressed	O	O
baseline	baseline	O	O
startle	startle	O	O
in	in	O	O
both	both	O	O
the	the	O	O
LES	les	O	O
and	and	O	O
FPS	fps	O	O
and	and	O	O
PTZ	ptz	S_chemical	O
suppressed	suppressed	O	O
baseline	baseline	O	O
startle	startle	O	O
in	in	O	O
the	the	O	O
FPS	fps	O	O
.	.	O	O

CONCLUSIONS	conclusions	O	O
:	:	O	O
In	in	O	O
contrast	contrast	O	O
to	to	O	O
findings	findings	O	O
in	in	O	O
the	the	O	O
FPS	fps	O	O
paradigm	paradigm	O	O
,	,	O	O
none	none	O	O
of	of	O	O
the	the	O	O
drugs	drugs	O	O
were	were	O	O
able	able	O	O
to	to	O	O
exacerbate	exacerbate	O	O
the	the	O	O
LES	les	O	O
response	response	O	O
.	.	O	O

Thus	thus	O	O
,	,	O	O
a	a	O	O
clear	clear	O	O
pharmacological	pharmacological	O	O
differentiation	differentiation	O	O
was	was	O	O
found	found	O	O
between	between	O	O
LES	les	O	O
and	and	O	O
FPS	fps	O	O
.	.	O	O

